Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
Atacicept demonstrates efficacy in systemic lupus erythematosus (SLE), reducing disease activity and severe flare while having an acceptable safety profile, especially in patients with high disease activity and serologically active disease, according to results from the phase IIb, multicentre ADDRESS II trial.
Patients with systemic lupus erythematosus (SLE) are prone to have cognitive impairment (CI), and the Montreal Cognitive Assessment (MoCA) appears to be a useful tool for detecting CI in SLE, according to a recent study. In addition, CI is less likely to occur in patients with more years of education.
Patients with systemic lupus erythematosus (SLE), compared to those without, have an increased risk of mortality after the first month following an ischaemic stroke, a recent study has found. In addition, functionality becomes poorer at 3 months.
Hydroxychloroquine provides significant immunomodulatory benefits to patients with systemic lupus erythematosus, with a study showing that the drug is associated with a mean reduction of 24.397 mg/dL in serum low-density lipid level.
Hospitalization, as well as rehospitalization within a short period of time, is common among patients with systemic lupus erythematosus (SLE), which is often caused by active SLE or infection, a recent study has found.
Current statin use does not contribute to an increased risk of developing systemic lupus erythematosus in individuals aged 40 years or above, according to a population-based cohort study. There is rather a signal of protection against the risk among long-term statin users.
The use of hydroxychloroquine (HCQ) and low-dose aspirin (ASA) appears to improve systemic lupus erythematosus (SLE), according to a recent study. This finding supports its continued use in patients with SLE.
Patients with juvenile-onset systemic lupus erythematosus (jSLE) have a higher frequency of renal involvement, cutaneous symptoms, oral ulcers, neuropsychiatric (NP) manifestations, autoimmune hemolytic anaemia (AIHA) and anti-dsDNA positivity than those with adult-onset SLE (aSLE), a recent study has found.
Enteric-coated mycophenolate sodium appears to be more effective than azathioprine at inducing long-term clinical remission and preventing relapse in patients with active systemic lupus erythematosus, according to the results of an open-label trial.
Etoricoxib exhibits a central mode of action and enhances pain and function in patients with painful knew osteoarthritis (OA), as presented in a randomised, double-blind, placebo-controlled, two-way crossover, four-week treatment study.
The addition of supervised physiotherapy to usual care does not provide clinically important improvement in the management of simple ankle sprains in a general population of patients seeking hospital-based acute care, according to results of a recent randomized controlled trial.
The toxic side-effects of chemotherapy appear to be induced by cell-free chromatin (cfCh) fragments released from dying cells, triggering DNA damage, apoptosis and inflammation in healthy cells, thereby exaggerating or amplifying the toxic effects caused by the drugs themselves, according to a study.